Witnessing the stock’s movement on the chart, on Thursday, Lyra Therapeutics Inc (NASDAQ: LYRA) set off with pace as it heaved 4.82% to $0.18, before settling in for the price of $0.17 at the close. Taking a more long-term approach, LYRA posted a 52-week range of $0.16-$6.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 58.51%. Meanwhile, its Annual Earning per share during the time was -21.63%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -6.83%. This publicly-traded company’s shares outstanding now amounts to $65.46 million, simultaneously with a float of $54.79 million. The organization now has a market capitalization sitting at $11.82 million. At the time of writing, stock’s 50-day Moving Average stood at $0.2185, while the 200-day Moving Average is $1.2400.
Lyra Therapeutics Inc (LYRA) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Lyra Therapeutics Inc’s current insider ownership accounts for 16.29%, in contrast to 46.47% institutional ownership.
Lyra Therapeutics Inc (LYRA) Earnings and Revenue Records
Lyra Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -6.83% and is forecasted to reach -0.64 in the upcoming year.
Lyra Therapeutics Inc (NASDAQ: LYRA) Trading Performance Indicators
Let’s observe the current performance indicators for Lyra Therapeutics Inc (LYRA). It’s Quick Ratio in the last reported quarter now stands at 3.64. The Stock has managed to achieve an average true range (ATR) of 0.02. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 8.04.
In the same vein, LYRA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.53, a figure that is expected to reach -0.13 in the next quarter, and analysts are predicting that it will be -0.64 at the market close of one year from today.
Technical Analysis of Lyra Therapeutics Inc (LYRA)
Going through the that latest performance of [Lyra Therapeutics Inc, LYRA]. Its last 5-days volume of 1.44 million was inferior to the volume of 1.7 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 28.81% While, its Average True Range was 0.0183.
Raw Stochastic average of Lyra Therapeutics Inc (LYRA) in the period of the previous 100 days is set at 9.97%, which indicates a major fall in contrast to 24.02% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 73.88% that was lower than 93.36% volatility it exhibited in the past 100-days period.
